marked.bio

oral SERD ยท small molecule

giredestrant

1 active trials, targeting ER. Not approved for any biomarker on marked.bio yet.

Also known as GDC-9545, RG6171.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
PIK3CA activating mutation 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of giredestrant.

  1. Roche 1

Trials

1 of 1 trials shown

  1. A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

    Recruiting Phase 2 Roche Started 2025Primary completion 2027-07 NCT07054190

    inavolisib FDA EUribociclibletrozolegiredestrant

    Confirmed PIK3CA mutation

    PIK3CA activating mutationBreast Cancer